What was the core news in the Healius (ASX:HLS) FY26 trading update?

Healius Limited announced a narrowing of its FY26 earnings guidance and the commencement of a comprehensive strategic review of its assets. The company now expects group underlying EBITDA to land between $259 million and $264 million, while underlying EBIT is projected at $30 million to $35 million.

Why is Healius (ASX:HLS) conducting a strategic review of its assets?

While not explicitly detailed, the review follows a period of fluctuating pathology volumes and rising regulatory labor costs. Management likely aims to identify underperforming segments or divestment opportunities to improve margins.

How is the Healius pathology division performing in 2026?

The pathology division is seeing a mix of steady revenue growth and softening volumes. Revenue grew by 3.5% in H1 FY26 and maintained a 2.4% growth rate through the first ten months of the year.

What impact does the Fair Work Commission’s ruling have on Healius (ASX:HLS)?

The Fair Work Commission's findings on gender-based undervaluation are creating immediate margin pressure by increasing labor costs. In Q4 FY26 alone, these regulatory adjustments are expected to add $1.8 million to pathology expenses.

Is Healius (ASX:HLS) successfully managing its operating expenses?

Yes, the company has demonstrated significant cost-containment capabilities despite inflationary and regulatory pressures. Healius reduced general pathology cost growth to 1.1% for the ten months ending April 2026, down from 1.9% in late 2025.

What is the bull case for Healius (ASX:HLS) after this update?

The bull case centers on the outperformance of Agilex Biolabs and successful cost-cutting measures. Agilex posted robust year-to-date revenue growth of 13.7%, proving to be a high-growth engine for the group.

What is the bear case for Healius (ASX:HLS) following this news?

The bear case focuses on structural labor cost increases and declining GP attendance, which fell 1.5% in H1 FY26. With the Fair Work Commission ruling mandating pay rises over the next five years, Healius faces a long-term headwind to its pathology margins.

Healius updates FY26 guidance amid review

Written by Liezl GambePublished May. 12 2026Last Updated May. 12 2026

Australian healthcare giant Healius (ASX:HLS) has issued a trading update for the 2026 financial year, concurrently announcing a comprehensive strategic review of its assets.

The company has narrowed its earnings guidance, projecting a group underlying EBITDA between $259 million and $264 million, with underlying EBIT expected to land between $30 million and $35 million.

While the company’s pathology division saw a 3.5% revenue increase in the first half of the year, more recent figures for the ten months ended April 2026 show a slight volume decline of 0.4%, though revenue maintained a 2.4% growth trajectory.

A critical factor impacting the company’s bottom line is the Fair Work Commission’s findings regarding gender-based undervaluation.

The regulatory adjustments are expected to increase pathology labour costs by $1.8 million in the final quarter of FY26.

Pathology collectors already began receiving these increases in April, with further phased pay rises scheduled for health professionals over the next five years.

Despite these mounting cost pressures, Healius has successfully contained general pathology cost growth to 1.1%, down from 1.9% in late 2025, through rigorous labour efficiencies.

Meanwhile, the company’s Agilex Biolabs remains a bright spot, posting robust revenue growth of 13.7% year-to-date.